Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab long-term extension with randomized treatment withdrawal in moderate to severe hidradenitis suppurativa
MOH_2020-06-24_009073Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (4 arms), sponsored by Novartis. Started Jun 2020; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2020-06-24_009073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-24_009073.